0001677077-17-000001.txt : 20170822 0001677077-17-000001.hdr.sgml : 20170822 20170822165718 ACCESSION NUMBER: 0001677077-17-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170822 DATE AS OF CHANGE: 20170822 EFFECTIVENESS DATE: 20170822 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alzamend Neuro, Inc. CENTRAL INDEX KEY: 0001677077 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811822909 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-293300 FILM NUMBER: 171045642 BUSINESS ADDRESS: STREET 1: 50 W. BROADWAY STREET 2: 3RD FLOOR CITY: SALT LAKE CITY STATE: X1 ZIP: 84101 BUSINESS PHONE: 9493465822 MAIL ADDRESS: STREET 1: 50 W. BROADWAY STREET 2: 3RD FLOOR CITY: SALT LAKE CITY STATE: X1 ZIP: 84101 D 1 primary_doc.xml X0708 D LIVE 0001677077 Alzamend Neuro, Inc. 50 W. BROADWAY SUITE 300 SALT LAKE CITY UT UTAH 84101 (949) 346-5822 DELAWARE None None Corporation true 2016 Philip Mansour 50 W. Broadway Suite 300 Salt Lake City UT UTAH 84101 Executive Officer Director President, Chief Executive Officer & Director Milton C Ault III 50 W. Broadway Suite 300 Salt Lake City UT UTAH 84101 Director Chairman William B Horne 50 W. Broadway Suite 300 Salt Lake City UT UTAH 84101 Executive Officer Director Chief Financial Officer & Director Biotechnology No Revenues 06b false true false true false 10000 Spartan Capital Securities, LLC 146251 None None 45 Broadway 9th Floor New York NY NEW YORK 10006 All States false 4000000 0 4000000 false 0 1800000 true 0 (1) 10% of the Offering proceeds and (2) if more than $2.5M is raised, (a) maximum of $1.4M on a pro rata basis, under a consulting agreement, and (b) 20M shares of our Common Stock from the Issuer's affiliate, under a separate consulting agreement. 0 false Alzamend Neuro, Inc. Philip Mansour Philip Mansour President & CEO 2017-08-22